May 2020. The company Chemotargets –based in the Barcelona Science Park and a global leader in the development of computational platforms for the design, optimization and safety evaluation of drugs– has signed a strategic agreement with the Hospital del Mar Medical Research Institute (IMIM) in order to accelerate research projects for the discovery and development of new oncological therapies that respond to important unmet medical needs. This public-private partnership will establish a framework for collaboration that promotes the creation of synergies between the IMIM experience in the identification of new therapeutic targets in emerging fields of cancer biology and the Chemotargets expertise in drug discovery and development. This initiative will include the use of cutting-edge computational technologies developed specifically to rapidly design drug candidates acting on new mechanisms of action or directed to targets that are difficult to address and for which no identified drugs currently exist. The IMIM Cancer Research Program develops pioneering research in areas such as cancer biology, understanding new mechanisms of tumor progression and evaluating new therapies such as immunotherapy, or detecting markers of response to treatment. oncological. This program contributes to the creation of new treatments and strategies that optimize therapies from the beginning, avoiding ineffective treatments with multiple side effects, and progressing more and more towards a personalized high-quality technical medicine that increases cure rates and improves the quality of lifetime. Thanks to the computational technology that Chemotargets will provide, the process will be easier and faster and drugs that act on targets or mechanisms for which there is currently no effective treatment can be identified. “This alliance is fully aligned with XXXX's main mission, which is to produce relevant science for patients. As a research institute of the Hospital de Mar, the IMIM has the strength of being very close to current medical needs. Through this alliance with Chemotargets, it will be possible to boost translational research at IMIM and respond to problems in a field as relevant as cancer", explains Xx. Xxxxxxx Xxxxxxx, director of IMIM, director of Research at the Barcelona MAR Health Park and Research Professor XXXXX. With this strategic agreement, Chemotargets kicks off a new stage of the company's growth. Since achieving a leading position in the global market as a provider of i...
May 2020. Upon final approval by the Division of Procurement Services, a case details page will be made part of this contract.
May 2020. 13.12.1 City and District complete design of school and Centerville Joint Use Park, and District submits plans and specifications to DSA for review (approximately 18 months from beginning of design in March 2019).
May 2020. 30.1 The delivery date of the goods and services is: goods and services delivery date 1 [●] [●] 2 [●] [●] 3 [●] [●]
May 2020. This is a template for contracting Third Parties whose Programme proposal has been accepted by the Strategic Portfolio Management Team. In accordance with Clause 20.6 of the ESCulab Consortium Agreement, it may be modified only if necessary and upon agreement with the Compound Owners and other ESCulab Beneficiaries whose rights are affected, provided it does not conflict with the content of the ESCulab Consortium Agreement (including but not limited to the access rights, compensations and options to be granted and Clause 20). Contributing Third Party Agreement For Programme Screening under IMI2-ESCulab Project THIS CONTRIBUTING THIRD PARTY AGREEMENT (the “Agreement”) effective as of XX (the “Effective Date”) is made BETWEEN:
